Spero reports Q3 2026 results, plans SP001 Phase 2 in IgG4-RD for Q2 2027Nov 12Quarterly updateSpero Therapeutics, Inc.
Spero reports Q2 2026 results, highlights Utebzi approval and Innovent license for SP001Aug 12Quarterly updateSpero Therapeutics, Inc.tebipenem pivoxil